Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:DMKNASDAQ:PHIONASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.60+9.5%$0.41$0.30▼$3.33$12.91M-1.381.63 million shs2.41 million shsDMKDMK Pharmaceuticals$0.17$0.18▼$21.70$2.34M1.111.16 million shs24.16 million shsPHIOPhio Pharmaceuticals$2.18-4.0%$2.15$0.97▼$9.79$10.87M0.842.44 million shs120,268 shsSNSESensei Biotherapeutics$8.06+5.2%$7.15$5.00▼$17.40$9.65M0.145,238 shs17,736 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+9.55%+96.19%+50.63%+41.60%-74.14%DMKDMK Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHIOPhio Pharmaceuticals-3.96%-12.10%+24.57%+67.05%-64.64%SNSESensei Biotherapeutics+5.22%+23.62%+36.38%-11.12%-38.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.8067 of 5 stars3.55.00.00.02.11.70.0DMKDMK PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals3.1011 of 5 stars3.55.00.00.01.12.50.6SNSESensei Biotherapeutics4.4564 of 5 stars3.75.00.04.80.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.001,227.80% UpsideDMKDMK Pharmaceuticals 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00542.20% UpsideSNSESensei Biotherapeutics 3.33Buy$90.001,016.63% UpsideCurrent Analyst Ratings BreakdownLatest DMK, ACXP, PHIO, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/2/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$100.005/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.005/1/2025SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/28/2025SNSESensei BiotherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $80.003/28/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/ADMKDMK Pharmaceuticals$3.62M0.00N/AN/A($0.38) per share0.00PHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$30.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$0.70N/AN/AN/AN/A-526.78%-223.78%8/8/2025 (Estimated)DMKDMK Pharmaceuticals-$26.48MN/A0.00N/AN/A-630.85%N/A-251.02%N/APHIOPhio Pharmaceuticals-$7.15M-$10.92N/A0.58N/AN/A-105.65%-89.19%8/13/2025 (Estimated)SNSESensei Biotherapeutics-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)Latest DMK, ACXP, PHIO, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A5/6/2025Q1 2025SNSESensei Biotherapeutics-$4.20-$5.40-$1.20-$0.27N/AN/A3/28/2025Q4 2024SNSESensei Biotherapeutics-$5.40-$5.40N/A-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ADMKDMK PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.931.93DMKDMK PharmaceuticalsN/A0.580.54PHIOPhio PharmaceuticalsN/A10.5810.58SNSESensei BiotherapeuticsN/A6.826.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%DMKDMK Pharmaceuticals38.55%PHIOPhio Pharmaceuticals57.31%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals26.00%DMKDMK Pharmaceuticals5.90%PHIOPhio Pharmaceuticals0.59%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals323.48 million17.38 millionOptionableDMKDMK Pharmaceuticals1110.10 million9.51 millionNo DataPHIOPhio Pharmaceuticals104.80 million4.77 millionNot OptionableSNSESensei Biotherapeutics401.26 million968,000Not OptionableDMK, ACXP, PHIO, and SNSE HeadlinesRecent News About These CompaniesSensei Biotherapeutics to execute 1-for-20 reverse stock splitJune 13, 2025 | kalkinemedia.comSensei Biotherapeutics Announces 1-for-20 Reverse Stock SplitJune 13, 2025 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressMay 6, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 2, 2025 | globenewswire.comSensei Biotherapeutics announces initial results from solnerstotug trial portionMarch 29, 2025 | markets.businessinsider.comSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Rockets on FY ’24 ResultsMarch 29, 2025 | baystreet.caSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 29, 2025 | markets.businessinsider.comSensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical ProgressMarch 28, 2025 | globenewswire.comSensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant TumorsMarch 27, 2025 | globenewswire.comWhat Makes Sensei Biotherapeutics (SNSE) a New Buy StockFebruary 6, 2025 | zacks.comSensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | markets.businessinsider.comSensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comSensei Biotherapeutics Inc (SNSE) Stock: Unveiling Its Hidden StrengthsJanuary 18, 2025 | bovnews.comSensei Biotherapeutics provides update, highlights key upcoming milestonesJanuary 9, 2025 | markets.businessinsider.comPromising Outlook for Sensei Biotherapeutics: Buy Rating Backed by SNS-101 Development and Financial ProjectionsJanuary 9, 2025 | markets.businessinsider.comSensei Biotherapeutics Inc (SNSE) Stock Trading RecapJanuary 9, 2025 | bovnews.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesJanuary 8, 2025 | globenewswire.comSensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare ConferenceNovember 28, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMK, ACXP, PHIO, and SNSE Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.60 +0.05 (+9.55%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$0.59 -0.01 (-2.07%) As of 06/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.DMK Pharmaceuticals NASDAQ:DMKDMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.Phio Pharmaceuticals NASDAQ:PHIO$2.18 -0.09 (-3.96%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.22 +0.04 (+2.06%) As of 06/23/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Sensei Biotherapeutics NASDAQ:SNSE$8.06 +0.40 (+5.22%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$8.04 -0.03 (-0.31%) As of 06/23/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
